Journal article

Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers

Sharlene Kaye, Josep Antoni Ramos-Quiroga, Geurt van de Glind, Frances R Levin, Stephen V Faraone, Steve Allsop, Louisa Degenhardt, Franz Moggi, Csaba Barta, Maija Konstenius, Johan Franck, Arvid Skutle, Eli-Torild Bu, Maarten WJ Koeter, Zsolt Demetrovics, Mate Kapitany-Foeveny, Robert A Schoevers, Katelijne van Emmerik-van Oortmerssen, Pieter-Jan Carpentier, Geert Dom Show all

Journal of Attention Disorders | SAGE PUBLICATIONS INC | Published : 2019


OBJECTIVE: To examine ADHD symptom persistence and subtype stability among substance use disorder (SUD) treatment seekers. METHOD: In all, 1,276 adult SUD treatment seekers were assessed for childhood and adult ADHD using Conners' Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; CAADID). A total of 290 (22.7%) participants met CAADID criteria for childhood ADHD and comprise the current study sample. RESULTS: Childhood ADHD persisted into adulthood in 72.8% (n = 211) of cases. ADHD persistence was significantly associated with a family history of ADHD, and the presence of conduct disorder and antisocial personality disorder. The combi..

View full abstract


Awarded by Plan Nacional sobre Drogas, Ministerio de Sanidad y Politica Social

Awarded by Swiss Foundation of Alcohol Research

Awarded by European Social Fund

Awarded by Australian NHMRC Principal Research Fellowship

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: In the period of development of the IASP study (2005-2010), the ICASA network received unrestricted grants from the following pharmaceutical companies: Janssen-Cilag, Eli Lilly & Company, and Shire. Since becoming a formal foundation (September 2010), the ICASA Foundation ( has operated independently from pharmaceutical funding, obtaining funding via the following sources: (a) participating institutes and (b) the Noaber Foundation, the Waterloo Foundation, and the Augeo Foundation. The funding companies, institutes, and foundations did not have, and will not have, influence on any aspect of the study, including research questions, data sampling, data management, data analyses, and publishing results. The ICASA Foundation arranged with institutes participating in the IASP study that each of these institutes would seek funding for their regional processes and data sampling efforts. The local institutes report the following funding sources: The Netherlands, Amsterdam: No external funding was obtained. The participating institute, Arkin, paid for the costs involved and used funding from Fonds Nuts Ohra for this project. Norway, Bergen Clinics Foundation: Main external funding has been the Regional research council for addiction in West Norway (Regionalt kompetansesenter for rusmiddelforskning i Helse Vest [KORFOR]), funding a 50% position. The remaining resources, including staff and infrastructure, have been from the Bergen Clinics Foundation. Norway, Fredrikstad: The IASP was funded by the hospital, Sykehuset Ostfold HF, not with money, but with 50% of the salary of the participating professionals; the Regional Centre of Dual Diagnosis; and the Social and Health directory. Sweden, Stockholm: The study was funded by the Stockholm Centre for Dependency Disorders. Belgium: The IASP project in Belgium received private funding. France, Bordeaux: Financial support was received from a Research Grant PHRC (2006-2012) from the French Ministry of Health and a French National Research Agency PRA-CNRS-CHU-Bordeaux award (2008-2010). Spain, Barcelona: Financial support was received from Plan Nacional sobre Drogas, Ministerio de Sanidad y Politica Social (PND 0080/2011); the Agencia de Salut Publica de Barcelona; and the Departament de Salut, Government of Catalonia, Spain. Switzerland, Berne/Zurich: The IASP in Switzerland was funded by the Swiss Foundation of Alcohol Research (Grant No. 209). Hungary, Budapest: Financial support for this project was received from The European Union and the European Social Fund (Grant No. TAMOP 4.2.1./B-09/1/KMR2010-0003). Australia, Sydney/Perth: The IASP Screening Phase was funded by a Curtin University Strategic Research Faculty Grant. The National Drug and Alcohol Research Centre at UNSW Australia and the National Drug Research Institute at Curtin University are supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. L.D. is supported by an Australian NHMRC Principal Research Fellowship (No. 1041742). USA, Syracuse: No funding was obtained.